Faculty Profiles - NASU Yasutomo

Papers - NASU Yasutomo

Division display 441 - 460 of about 612 ／ All the affair displays >>

Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus Calmette-Guerin therapy Reviewed

Takanori Murakami, Shin Ebara, Takashi Saika, Shin Irie, Katsuji Takeda, Yoshio Maki, Sadayuki Miyaji, Daisuke Manabe, Haruki Kaku, Yasutomo Nasu, Tomoyasu Tsushima, Hiromi Kumon

ACTA MEDICA OKAYAMA 61 ( 6 ) 341 - 344 2007.12

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

We evaluated the need for transurethral biopsy at first follow-up after intravesical. bacillus Calmette-Guerin (BCG) therapy for superficial bladder cancer. The records of 84 patients with superficial bladder cancer who received a 6- or 8-week course of BCG were reviewed. Pathological results before BCG, cystoscopic findings, urinary cytology, and biopsy results for evaluation of BCG therapy were reviewed. All 19 patients with positive urinary cytology had evidence of positive bladder biopsy results. Fifty-three of 54 patients (98.1 %) with no visible recurrent tumor and negative urinary cytology demonstrated negative pathological results on bladder biopsy. When not found in conjunction with positive urinary cytology, erythematous mucosa on cystoscopy was not an indicator of tumor recurrence or residual cancer. In conclusion, routine transurethral biopsy of the bladder for evaluating the response to BCG intravesical therapy is not necessary in patients who have no visible tumor on cystoscopy and negative urinary cytology.

Web of Science

researchmap

The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer Reviewed

Shin Ebara, Daisuke Manabe, Yasuyuki Kobayashi, Ryuta Tanimoto, Takashi Saika, Yasutomo Nasu, Shirou Saito, Takefumi Satoh, Kenta Miki, Katsuyoshi Hashine, Hiromi Kumon

ACTA MEDICA OKAYAMA 61 ( 6 ) 335 - 340 2007.12

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

From September 2003 to December 2005, 188 patients who visited our hospital and allied institutions for the purpose of prostate brachytherapy were administrated hormonal therapy for volume reductions before brachytherapy. The pretreatment and posttreatment of prostate volume using a transrectal ultrasound volumetric study and the types and duration of hormonal therapy were analyzed. We administered 91 patients with Luteinizing hormone-releasing hormone (LH-RH) agonis, 49 patients with anti-androgen (bicaltamide/flutamide), and 48 patients with maximum androgen blockade (MAB). The duration of the hormonal therapy was 1-3 months for 49 patients, 4-6 months for 59 patients, 7-9 months for 40 patients, 10-12 months for 32 patients, and over 13 months for 8 patients. Before the initiation of hormonal therapy, the mean prostate volume was 35.12 ml (11.04-78.71 ml), and the average of prostate volume before and after hormonal therapy was 36.79 ml and 24.79 ml, respectively (a 32.4 % reduction). The prostate volume reduction rate was 32.0 % for the LH-RH agonist only, 18.1 % for the anti-androgen only and 41.2 % for the NUB. No statistically significant difference was observed for the duration of hormonal therapy between 3 groups. A three-month course of the neoadjuvant LH-RH agonist indicated a sufficient volume reduction effectiveness for a large prostate volume.

Web of Science

researchmap

Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model Reviewed

K. Edamura, Y. Nasu, M. Takaishi, T. Kobayashi, F. Abarzua, M. Sakaguchi, Y. Kashiwakura, S. Ebara, T. Saika, M. Watanabe, N-H Huh, H. Kumon

CANCER GENE THERAPY 14 ( 9 ) 765 - 772 2007.9

Language：English Publishing type：Research paper (scientific journal) Publisher：NATURE PUBLISHING GROUP

We had previously reported that REIC/Dkk-3, a member of the Dickkopf ( Dkk) gene family, works as a tumor suppressor. In this study, we evaluated the therapeutic effects of an intratumoral injection with adenoviral vector encoding REIC/Dkk-3 gene ( Ad-REIC) using an orthotopic mouse prostate cancer model of RM-9 cells. We also investigated the in vivo anti-metastatic effect and in vitro anti-invasion effect of Ad-REIC gene delivery. We demonstrated that the Ad-REIC treatment inhibited prostate cancer growth and lymph node metastasis, and prolonged mice survival in the model. These therapeutic responses were consistent with the intratumoral apoptosis induction and in vitro suppression of cell invasion/migration with reduced matrix metalloprotease-2 activity. We thus concluded that in situ Ad-REIC/Dkk-3 gene transfer may be a promising therapeutic intervention modality for the treatment of prostate cancer.

DOI： 10.1038/sj.cgt.7701071

Web of Science

researchmap

体腔鏡下腎尿管全摘除術の上部尿路上皮癌に対する治療成績

小武家誠, 雑賀隆史, 小林泰之, 上原慎也, 那須保友, 公文裕巳, 真鍋大輔, 入江伸, 津島知靖, 山田大介

日本癌治療学会誌 42 ( 2 ) 552 - 552 2007.9

Health-related quality of life after radical cystectomy for bladder cancer in elderly patients with an ileal conduit, ureterocutaneostomy, or orthotopic urinary reservoir: A comparative questionnaire survey Reviewed

Takashi Saika, Ryoji Arata, Tomoyasu Tsushima, Yasutomo Nasu, Bunzo Suyama, Katsuji Takeda, Shin Ebara, Daisuke Manabe, Tomoko Kobayashi, Ryuta Tanimoto, Hiromi Kumon

ACTA MEDICA OKAYAMA 61 ( 4 ) 199 - 203 2007.8

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

To compare the health-related quality of life of elderly patients after radical cystectomy for bladder cancer in urinary diversion groups: ileal conduit, ureterocutaneostomy, or orthotopic urinary reservoir. The 109 participating elderly patients aged 75 or older completed self-reporting questionnaires: the QNQ-C30, and on satisfaction with urinary diversion methods. Fifty-six patients had undergone constructions for ileal conduit diversion, 31 for ureterocutaneostomy, and 22 for orthotopic urinary reservoir (OUR). The median follow-up period for each group was 4.0 years (range 0.3-11.2), 4.5 years (range 0.3-18.0), and 3.3 years (range 0.3-6.7), respectively. Regardless of the type of urinary diversion, the majority of patients reported having good overall quality of life, although with some problem of pain. No significant differences among urinary diversion subgroups were found in any quality of life area in the QLQ-C30 questionnaire. More patients in the OUR sub-group felt disappointment than those in the ileal conduit or cutaneostomy sub-groups. However, a questionnaire which asked which diversion method would be preferable showed a trend that more patients in the OUR subgroup would have chosen the same one. Health-related quality of life appeared relatively good in these 3 groups. Patient demands and expectations may be so different from the results that the details of each urinary diversion method should be explained thoroughly. OUR construction could be a candidate even for elderly patients.

Web of Science

researchmap

Orthotopic ileal neobladder versus sigmoidal neobladder: A "Quality of life" (QOL) survey Reviewed

Ryoji Arata, Takashi Saika, Tomoyasu Tsushima, Fernando Abarzua, Yasutomo Nasu, Hiromi Kumon

ACTA MEDICA OKAYAMA 61 ( 4 ) 229 - 234 2007.8

Language：English Publishing type：Research paper (scientific journal) Publisher：OKAYAMA UNIV MED SCHOOL

To compare the quality of life (QOL) in patients with ileal neobladder and sigmoidal neobladder, a retrospective survey was conducted using a formulated questionnaire. Between January and March 1999, a QOL survey was conducted using self-administered questionnaires (EORTC QLQ-C30, IPSS, supplemented with detailed questionnaires about continence, sexual function, and patient's satisfaction with the selected urinary diversion method) for 78 patients with orthotopic urinary reservoir (OUR) who were followed-up for more than 3 months after cystectomy. Among 78 patients, 63 had OUR using an ileal segment (male/female 59/4, median age: 70.8 years old, median follow-up: 1.7 years). Fifteen patients had OUR using a sigmoidal segment (male/female = 13/2, median age: 71.9, median follow-up: 3.9). The QLQ-C30 functional evaluation and the items in relation to sexual function showed no differences between the 2 groups. Concerning the voiding condition, bladder emptying, frequency, and urgency, scores in the sigmoidal OUR group were significantly higher. The QOL score concerning voiding conditions, daytime, and nighttime continence and quantity of pad showed a better score in the ileal OUR group. Concerning the satisfaction with methods of urinary diversion, patients in the sigmoidal OUR group expressed less satisfaction than their preoperative expectations. Considering several postoperative voiding conditions, ileal OUR seems superior to sigmoidal OUR.

Web of Science

researchmap

Natural course of lower urinary tract symptoms following discontinuation of alpha-1-adrenergic blockers in patients with benign prostatic hyperplasia Reviewed

Teruhiko Yokoyama, Toyohiko Watanabe, Takashi Saika, Yasutomo Nasu, Hiromi Kumon, Yoshiyuki Miyaji, Atsushi Nagai

INTERNATIONAL JOURNAL OF UROLOGY 14 ( 7 ) 598 - 601 2007.7

Language：English Publishing type：Research paper (scientific journal) Publisher：BLACKWELL PUBLISHING

Objectives: alpha 1-adrenergic blockers (alpha b) remain the first-line therapy in men with lower urinary tract symptoms (LUTS). The current published work advocates continued use of alpha b for their effect to be maintained. However, some patients decide to discontinue use of the medication after their symptoms are relieved and can keep good conditions. In this study, we investigated the natural course of LUTS after the discontinuation of successful treatment of alpha b.
Methods: Among 75 patients with LUTS who stopped alpha b medication once their symptoms improved, 60 patients (age, 50-87 years; median, 70) who could be followed for at least 12 months after discontinuation of alpha b were analyzed in this study. Evaluations included a clinical determination of the International Prostate Symptom Score (IPSS), peak flow rate (Qmax) and postvoid residual urine volume (PVR). Upon patient request or in cases of PVR more than 100 mL, administration of alpha b was resumed.
Results: Eighteen out of the 60 patients (30%) asked for re-treatment within 12 months after discontinuation (re-treatment group). The other 42 patents were able to maintain good condition without medication (discontinuation group). The IPSS was 15.9, 8.7, 10.1, 10.2, 9.7, 8.8 and 9.0, on the first visit, just before discontinuation, and 1, 3, 6, 9 and 12 months after stopping treatment among the discontinuation group, respectively. Similarly, Qmax was 10.6, 14.8, 14.2, 14.3, 14.7, 13.2 and 13.6 mL/ s, respectively. Treatment periods, prostatic volume and peak flow rates just before discontinuation of medication differed significantly between the re-treatment and discontinuation group.
Conclusions: In spite of the short follow-up periods, these results suggest that selected patients with relatively small prostatic volume and good flow rates after therapy can discontinue alpha b medication after their symptoms improve.

DOI： 10.1111/j.1442-2042.2007.01784.x

Web of Science

PubMed

researchmap

Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3 Reviewed

Fernando Abarzua, Masakiyo Sakaguchi, Ryuta Tanimoto, Hiroyuki Sonegawa, Dai-Wei L, Kohei Edamura, Tomoko Kobayashi, Masami Watanabe, Yuji Kashiwakura, Haruki Kaku, Takashi Saika, Keiichiro Nakamura, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20 ( 1 ) 37 - 43 2007.7

Language：English Publishing type：Research paper (scientific journal) Publisher：PROFESSOR D A SPANDIDOS

We recently showed that overexpression of REIC/Dickkopf-3 (Dkk-3), a tumor suppressor gene, induced apoptosis in a tumor cell-specific manner. The aim of the present study was to determine the mechanisms underlying the selective induction of apoptosis. At first, we found a mouse renal carcinoma cell line, RENCA, to be extremely sensitive to an adenovirus carrying REIC/Dkk-3 (Ad-REIC), and we showed that activation of c-Jun N-terminal kinase (JNK) was a critical step in cell death, i.e. a process similar to that in human prostate and testicular cancer observed in our previous studies. Among the proteins interfering with the activation of JNK, heat shock protein (Hsp)70/72 was reduced in expression in RENCA cells compared with that in NIH3T3 cells. An Hsp70/72 inducer protected RENCA cells from Ad-REIC-induced apoptosis, while an Hsp70/72 inhibitor sensitized NIH3T3 cells for apoptosis induction. These results indicate that functionally active Hsp70/72 is a key factor in tumor cell-specific induction of apoptotic cell death and that analyses of the expression levels of Hsp70/72 may be essential in determining the significance of Ad-REIC-based gene therapy against human cancer.

Web of Science

researchmap

Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles Reviewed

Kenji Tamura, Mutsuo Furihata, Tatsuhiko Tsunoda, Shingo Ashida, Ryo Takata, Wataru Mara, Hiroki Yoshioka, Yataro Daigo, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Konaka, Mikio Namiki, Keiichi Tozawa, Kenjiro Kohri, Nozomu Tanji, Masayoshi Yokoyama, Toru Shimazui, Hideyuki Akaza, Yoichi Mizutani, Tsuneharu Miki, Tomoaki Fujioka, Taro Shuin, Yusuke Nakamura, Hidewaki Nakagawa

CANCER RESEARCH 67 ( 11 ) 5117 - 5125 2007.6

Language：English Publishing type：Research paper (scientific journal) Publisher：AMER ASSOC CANCER RESEARCH

One of the most critical issues in prostate cancer clinic is emerging hormone-refractory prostate cancers (HRPCs) and their management. Prostate cancer is usually androgen dependent and responds well to androgen ablation therapy. However, at a certain stage, they eventually acquire androgen-independent and more aggressive phenotype and show poor response to any anticancer therapies. To characterize the molecular features of clinical HRPCs, we analyzed gene expression profiles of 25 clinical HRPCs and 10 hormone-sensitive prostate cancers (HSPCs) by genome-wide cDNA microarrays combining with laser microbeam microdissection. An unsupervised hierarchical clustering analysis clearly distinguished expression patterns of HRPC cells from those of HSPC cells. In addition, primary and metastatic HRPCs from three patients were closely clustered regardless of metastatic organs. A supervised analysis and permutation test identified 36 up-regulated genes and 70 down-regulated genes in HRPCs compared with HSPCs (average fold difference > 1.5; P < 0.0001). We observed overexpression of AR, ANLN, and SNWPE and down-regulation of NR4A1, CYP27A1, and HLA-A antigen in HRPC progression. AR overexpression is likely to play a central role of hormone-refractory phenotype, and other genes we identified were considered to be related to more aggressive phenotype of clinical HRPCs, and in fact, knockdown of these overexpressing genes by small interfering RNA resulted in drastic attenuation of prostate cancer cell viability. Our microarray analysis of HRPC cells should provide useful information to understand the molecular mechanism of HRPC progression and to identify molecular targets for development of HRPC treatment.

DOI： 10.1158/0008-5472.CAN-06-4040

Web of Science

researchmap

Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy Reviewed International journal

Nasu Yasutomo, Saika Takashi, Ebara Shin, Kusaka Nobuyuki, Kaku Haruki, Abarzua Fernando, Manabe Daisuke, Thompson Timothy C, Kumon Hiromi

MOLECULAR THERAPY 15 ( 4 ) 834 - 840 2007.4

Language：English Publishing type：Research paper (scientific journal)

We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as the first prostate cancer gene therapy trial. Major inclusion criteria were local recurrence of prostate cancer after hormonal therapy and no metastasis. Adv.HSV-tk was injected directly into the prostate in escalating doses from 10(9) to 10(10) infection units, followed by intravenous administration of GCV for 14 days. Eight patients received nine courses of this gene therapy. The detection of vector DNA in blood/urine was only transient and no remarkable adverse events were observed in any patient. With regard to clinical response, significant prolongation of the median serum prostate-specific antigen (PSA) doubling time from 2.9 to 6.2 months (P = 0.041) was detected. In five patients (six injections), a clear decrease of PSA values was observed. One patient showed repeated clinical response after repeated injections. Serum cytokine analysis showed no notable changes after treatment. Fluorescence-activated cell sorting analysis also showed no influence on phenotypic distribution in peripheral blood samples, except for an increasing trend of CD8(+)/HLA-DR(+) after therapy. This study confirmed the safety profile and possibility of clinical response at the surrogate marker level in a clinical trial of HSV-tk gene therapy for hormone-refractory prostate cancer.

DOI： 10.1038/mt.sj.6300096

Web of Science

PubMed

researchmap

Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma Reviewed

Daisuke Manabe, Takashi Saika, Shin Ebara, Shinya Uehara, Atsushi Nagai, Ryuji Fujita, Shin Irie, Daisuke Yamada, Tomoyasu Tsushima, Yasutomo Nasu, Hiromi Kumon

UROLOGY 69 ( 3 ) 457 - 461 2007.3

Language：English Publishing type：Research paper (scientific journal) Publisher：ELSEVIER SCIENCE INC

OBJECTIVES To determine the oncologic safety of laparoscopic nephroureterectomy (LNU), we compared the long-term oncologic outcome of LNU versus open nephroureterectomy (ONU) in patients with upper tract transitional cell carcinoma.
METHODS A total of 367 nephroureterectomy procedures were performed at our institutes for upper tract transitional cell carcinoma without distant metastases. Of 224 patients without concomitant or previous bladder cancer, 58 underwent LNU with open intact specimen retrieval plus open distal ureter and bladder cuff removal and 166 underwent ONU. Their data were reviewed and analyzed retrospectively. The mean follow-up was 13.6 months (range 14 to 34) for the LNU group and 28.0 months (range 14 to 36) for the ONU group.
RESULTS Bladder recurrence was recognized in 19 patients (32.8%) after LNU at a median follow-up of 5.6 months compared with 63 patients (38.0%) after ONU. Local recurrence only developed in 2 patients (1.1%) after ONU. One port site metastasis occurred in a patient who had undergone LNU. Distant metastases developed in 10 patients (17.2%) after LNU and 33 patients (19.9%) after ONU. The frequency of bladder recurrence, local recurrence, and distant metastases did not differ significantly between the two groups. The actual disease-free 2-year survival rates were similar (75.6% versus 81.7%). In all patients, the risk of metastases and death increased with advanced tumor stage and grade, but not by surgical procedure.
CONCLUSIONS In the surgical management of upper tract transitional cell carcinoma, LNU does not negatively affect long-term oncologic control and can be considered an alternative modality. Tumor stage and grade are, however, important prognostic factors in the incidence of metastases and cancer-specific mortality.

DOI： 10.1016/j.urology.2006.11.005

Web of Science

researchmap

REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer Reviewed

Ryuta Tanimoto, Fernando Abarzua, Masakiyo Sakaguchi, Mikiro Takaishi, Yasutomo Nasu, Hiromi Kumon, Nam-Ho Huh

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 19 ( 3 ) 363 - 368 2007.3

Language：English Publishing type：Research paper (scientific journal) Publisher：PROFESSOR D A SPANDIDOS

Human testicular cancer is very sensitive to chemotherapy and radiation therapy and is regarded as a curable cancer. The cancer prevails in the young reproductive generation and testicular dysfunction is often observed as a side effect, remaining a serious challenge. In the present study, we examined the potential utility of REIC/Dkk-3-based gene therapy against human testicular cancer. Expression of REIC/Dkk-3 was reduced in all of the human seminoma and non-seminomatous germ cell tumor tissues. Overexpression of REIC/Dkk-3 using an adenovirus vector (Ad-REIC) induced apoptosis in a testicular germ cell cancer cell line NCCIT but not in normal human fibroblasts. c-Jun terminal kinase (JNK) was activated by Ad-REIC and the induction of apoptosis was abrogated by a JNK inhibitor. A single intratumoral injection of Ad-REIC markedly inhibited the tumorigenic growth of NCCIT cells in nude mice. These results indicate that Ad-REIC may lead to developing less insulting and non-genotoxic therapeutic measures against human testicular cancer.

Web of Science

researchmap

Primary aldosteronism caused by a unilateral adrenal adenoma accompanied by autonomous cortisol secretion

Suzuki J, Otsuka F, Inagaki K, Otani H, Miyoshi T, Terasaka T, Ogura T, Omori M, Nasu Y, Makino H

Hypertens Res 30 ( 4 ) 367 - 373 2007

Implication of Amphiphysin 1 and Dynamin 2 in Tubulobulbar Complex Formation and Spermatid Release

Kusumi Norihiro, Watanabe Masami, Yamada Hiroshi, Li Shun-Ai, Kashiwakura Yuji, Matsukawa Takashi, Nagai Atsushi, Nasu Yasutomo, Kumon Hiromi, Takei Kohji

Cell Struct. Funct. 32 ( 2 ) 101 - 113 2007

Language：English Publishing type：Research paper (scientific journal) Publisher：Japan Society for Cell Biology

Tubulobulbar complexes (TBCs) are composed of several tubular invaginations formed at the plasma membrane of testicular Sertoli cells. TBCs are transiently formed at the contact region with spermatids at spermatogenic stage VII in rat and mouse, and such TBC formation is prerequisite for spermatid release. Since the characteristic structure of TBCs suggests that the molecules implicated in endocytosis could be involved in TBC formation, we here investigated the localization and physiological roles of endocytic proteins, amphiphysin 1 and dynamin 2, at TBCs. We demonstrated by immunofluorescence that the endocytic proteins were concentrated at TBCs, where they colocalized with cytoskeletal proteins, such as actin and vinculin. Immunoelectron microscopy disclosed that both amphiphysin 1 and dynamin 2 were localized on TBC membrane. Next, we histologically examined the testis from amphiphysin 1 deficient {Amph^–/–} mice. Morphometric analysis revealed that the number of TBCs was significantly reduced in Amph^–/–. The ratio of stage VIII seminiferous tubules was increased, and the ratio of stage IX was conversely decreased in Amph^–/–. Moreover, unreleased spermatids in stage VIII seminiferous tubules were increased in Amph^–/–, indicating that spermatid release and the following transition from stage VIII to IX was prolonged in Amph^–/– mice. These results suggest that amphiphysin 1 and dynamin 2 are involved in TBC formation and spermatid release at Sertoli cells.<br>

DOI： 10.1247/csf.07024

CiNii Article

researchmap

PP-352 部分珊瑚状結石に対し、尿管アクセスシース (AquaGuide URETERAL ACCESS SHEATH) を用いて施行したTULの2例(第95回日本泌尿器科学会総会)

上原慎也, 門田晃一, 渡辺豊彦, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 98 ( 2 ) 484 - 484 2007

OP-045 無阻血と阻血による体腔鏡下腎部分切除術の周術期成績の比較検討(第95回日本泌尿器科学会総会)

小林泰之, 真鍋大輔, 江原伸, 雑賀隆史, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 98 ( 2 ) 302 - 302 2007

WS2-6 ヨウ素125永久挿入密封小線源治療後のQOLに関する研究(限局性前立腺癌に対する非観血的治療-各治療の有害事象とQOLへの影響を中心に, 第95回日本泌尿器科学会総会)

江原伸, 雑賀隆史, 真鍋大輔, 谷本竜太, 小林泰之, 那須保友, 公文裕巳

日本泌尿器科学会雑誌 98 ( 2 ) 190 - 190 2007

PP-686 体腔鏡下腎尿管全摘除術の上部尿路癌に対する治療成績 (第2報)(第95回日本泌尿器科学会総会)

真鍋大輔, 雑賀隆史, 江原伸, 上原慎也, 小林泰之, 那須保友, 公文裕巳, 伊藤誠一, 入江伸, 山田大介, 津島知靖

日本泌尿器科学会雑誌 98 ( 2 ) 568 - 568 2007

Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome

Toyohiko Watanabe, Shinya Uehara, Daishi Araki, Miyabi Inoue, Koichi Monden, Takashi Saika, Yasutomo Nasu, Hiromi Kumon, Teruhiko Yokoyama

Nishinihon Journal of Urology 69 ( 10 ) 578 - 583 2007

Language：Japanese Publishing type：Research paper (scientific journal)

Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.

Scopus

researchmap

Phase study of adenoviral vector delivery of HSV-tk gene and the intravenous administration of ganciclovir in men with local recurrence of prostate cancer after hormonal therapy Reviewed

Nasu Yasutomo, Kaku Haruki, Ebara Shin, Saika Takashi, Thompson Timothy C, Kumon Hiromi

JOURNAL OF GENE MEDICINE 8 ( 12 ) 1443 2006.12

　 PREV - NEXT 　

< NASU Yasutomo >

Papers - NASU Yasutomo